GSK: Result Summaries: Compounds > Haemophilus influenzae Type b Vaccine

Home > Result Summaries: Compounds > Haemophilus influenzae Type b Vaccine

Result Summaries: Haemophilus influenzae Type b Vaccine

Result Summaries for Haemophilus influenzae Type b Vaccine
GSK Study ID	Phase	Title	Summary (Download)
104124	Phase 4	Assess the safety & reactogenicity of GSK Biologicals Hib vaccine co-administered with Chinese local DTPw vaccine when compared to Chinese local DTPw vaccine administered alone, in healthy infants at 3,4 & 5 mths of age (0 citation(s))
208108/059	Phase 4	A post-marketing surveillance study of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b (Hib) tetanus conjugate vaccine in 3,000 Filipino subjects. (0 citation(s))
208108/084	Phase 3	An open study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals' Haemophilus influenzae type b vaccine administered at 2, 4, 6 months to healthy infants over 2 months of age as a primary vaccination course (1 citation(s))
208108/087	Phase 2	Phase 2 open randomized primary vaccination study to assess the immunogenicity and reactogenicity of GSK Bios Haemophilus influenzae type b conjugate vac admin with commercially available DTPw vac as compared to GSK Bios’ Hib admin mixed with GSK Bios’ DTPw vac in healthy infants (1 citation(s))
208108/091	Phase 2	Immunogenicity, safety and reactogenicity of GSK Biologicals’ Tritanrix™-HepB low thio/Hib2.5 Gödöllö compared to GSK Biologicals’ Tritanrix™-HepB/Hiberix™Gödöllö when administered as a 3-dose primary vaccination course to healthy infants (0 citation(s))
208108/091 (Hib-091) and 208108/092 (Hib-092)	Phase 2	A phase 2, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GSK Bios’ Tritanrix™-HepB/Hib2.5 to GSK Bios’ Tritanrix™-HepB/Hiberix™ when admin as a 3-dose primary vaccination course to healthy infants at 6-10-14 weeks of age (0 citation(s))
208108-083	Phase 4	A phase IV, open, multicentric, post-marketing surveillance study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b vaccine (Hiberix™) in Korean subjects administered according to the Prescribing Information. (0 citation(s))
208140/005p	Phase 3	Immunogenicity and reactogenicity of GSK’s DTPa-HBV vaccine and GSK’s Hib vaccine, when administered simultaneously in 2 separate injections or in one single injection, as a primary vaccination course to healthy infants at the age of 2, 4 and 6 months (0 citation(s))
208140/020	Phase 3	Immunogenicity & reactogenicity study of GSK’s DTPa-HBV & dtpa-HBV vaccines when administered with GSK’s Hib vaccine, either mixed and given in 1 single injection or given in 2 concomitant injections, as a booster vaccination at 15 to 22 months to healthy children, previously primed with a 3 doses of DTPa-HBV (0 citation(s))
208140/032	Phase 4	Open clinical study of the immunogenicity and reactogenicity of SB Biologicals’ DTPa-HBV vaccine, when coadministered with SB Biologicals’ Hib vaccine in 2 concomitant injections into opposite limbs, as a primary vaccination course in healthy infants aged 2, 4 and 6 months, followed by a booster at 18 months (0 citation(s))
208140/038	Phase 3	Immunogenicity and reactogenicity study of GSK’s DTPa HBV and Hib, either mixed or given in 2 concomitant injections, as a primary vaccination course to healthy infants at the age of 2, 4 and 6 months (0 citation(s))
213503/004	Phase 2/3	Immunogenicity and reactogenicity study of GSK’s combined diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, coadministered with GSK’s Haemophilus influenzae type b conjugate vaccine, either in 2 concomitant injections or mixed in one injection, given to healthy infants at 2, 4 and 6 months (1 citation(s))
213503/005	Phase 3	Consistency study in terms of immunogenicity & reactogenicity of 2 lots of GSK’s DTPa-IPV vaccine coadministered with GSK’s Hib vaccine, either simultaneously in 2 separate injections or mixed in 1 single injection, as a primary vaccination course to healthy infants at 2, 4 and 6 months (0 citation(s))
213503/013	Phase 2	Immunogenicity & reactogenicity study of coadministration of GSK’s DTPa-IPV vaccine & GSK’s Hib vaccine, either mixed & given in 1 single injection, or given in 2 concomitant injections, as a booster vaccination to healthy children, previously primed with a 3 dose primary vaccination course using same vaccine (0 citation(s))
213503/026	Phase 3	Reactogenicity and immunogenicity study of GSK’s DTPa coadministered with GSK’s Hib in 2 concomitant injections or mixed and to GSK’s DTPa-IPV mixed with GSK’s Hib, administered as a booster to healthy children in their second year of life, previously primed with 3 doses of GSK’s DTPa-HBV-IPV (0 citation(s))
217744/035	Phase 2	A booster vaccination study of one dose of GSK’s DTPa HBV IPV vaccine, coadministered with 2 formulations of GSK’s Hib conjugate vaccine, either mixed or injected in 2 concomitant injections, in healthy children who participated in Study 217744/011 (DTPa-HBV-IPV-011) or 217744/016 (DTPa-HBV-IPV-016) (0 citation(s))
347414/029	Phase 2	Multinational, randomised, controlled, open, phase 2 clinical study to evaluate the safety and immunogenicity of GSK Bios’ investigational vaccination regimen admin as a booster dose to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study (0 citation(s))
347414/036	Phase 3	AA phase-3, open, controlled study to assess the safety and immunogenicity of four different formulations of GSK Bio’s investigational vaccination regimen when administered as a booster to healthy infants, 12 to 16 months old, previously vaccinated in infancy in a primary study. (0 citation(s))
371594/006	Phase 2	A phase II, open, randomized study to assess the immune memory induced by a primary vaccination course of an investigational vaccination regimen and the immunogenicity and reactogenicity of a fourth dose of an investigational vaccination regimen, to healthy toddlers primed in study 371594/004. (0 citation(s))

Filter list by: